Novo Nordisk to test best-selling substance in stroke indication
A study at Aarhus University Hospital demonstrated that semaglutide reduced damage caused by ischemic strokes in rats. Now, Novo Nordisk will initate a phase II study in this indication.
by christian bundgaard, translated by catherine brett
Novo Nordisk is planning to test its best-selling substance semaglutide, which is already approved within the treatment of diabetes and obesity, in non-diabetic patients who have suffered severe ischemic strokes, trial database Clinical Trials reveals.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Zealand Pharma CEO has high hopes for obesity candidate
For subscribers
